Psoriasis

Perrigo Announces Commercial Launch of Betamethasone Valerate Foam

The product is the generic equivalent of Luxiq foam, intended for treatment of scalp psoriasis.

The Perrigo Company announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq® Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, Inc., which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition.

No votes yet

Perrigo Announces FDA Approval Of Betamethasone Valerate Foam 0.12%

The product, from the company’s partner firm Cobrek Pharmaceuticals Inc., is indicated for treatment of scalp psoriasis.

Perrigo Co. announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam. Perrigo has manufactured the product and is preparing to commence commercial shipments on January 15, 2013, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.

No votes yet

Royalty Pharma Acquires Fumapharm AG Assets

The purchase involves treatments for multiple sclerosis and psoriasis.

Royalty Pharma announces it has acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. 

No votes yet
Syndicate content